Additional Lots of Losartan Recalled


Manufacturer Torrent Pharmaceuticals Limited is recalling 36 additional lots[1] of the blood pressure drug losartan potassium and 68 additional lots of losartan-hydrochlorothiazide combination tablets due to detection of trace amounts of the carcinogen N-Methylnitrosobutyric acid (NMBA) above acceptable daily levels set by the U.S. Food and Drug Administration (FDA).

Advertisement

Information about the nationwide recall, including details on products and lots, is available on the FDA website[2].

To date, there have not been reports of adverse events related to this recall. To learn more about the recall, contact Torrent Pharmaceuticals at (800) 912-9561 or [email protected][3].

Endnotes:
  1. recalling 36 additional lots: https://www.medscape.com/viewarticle/912022?nlid=129410_3901&src=wnl_newsalrt_190419_MSCPEDIT&uac=92745PY&impID=1941706&faf=1
  2. available on the FDA website: https://www.fda.gov/Safety/Recalls/ucm636296.htm
  3. [email protected]: mailto:[email protected]

Source URL: https://www.diabetesselfmanagement.com/blog/additional-lots-of-losartan-recalled/


Diane Fennell: Diane Fennell has been an editor at Diabetes Self-Management magazine since 2003. She is currently the Editorial Director. (Diane Fennell is not a medical professional.)

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.